MDM2 and triple-negative breast carcinoma: Recently, a newly discovered MDM2-targeted PROTAC, YX-02-030 (derived from RG7112), is the first MDM2-targeted PROTAC to demonstrate anticancer activity against p53 mutant cells in triple negative breast cancer (TNBC) (Adams et al., 2023).